Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Content analysis
?| Positive | ||
| Negative | ||
| Uncertain | ||
| Constraining | ||
| Legalese | ||
| Litigous | ||
| Readability |
8th grade Avg
|
|
New words:
addressed, Ambrx, amivantamab, antibody, appellate, biology, Biopharma, biopharmaceutical, Blink, Bowel, brand, CAD, calcified, consensual, core, cosmetic, counterclaimed, declaratory, defamatory, deficiency, disaggregation, distributor, East, encouraged, environment, ERISA, expanded, fewer, firm, geographic, ii, iii, Inflammatory, insignificant, intravascular, InvaGen, INVOKANA, iv, IVL, Jamp, lithotripsy, LLT, Macroeconomic, maker, Maquet, mesothelioma, mismanaging, Mitsubishi, Nasdaq, Orthopaedic, PAD, parallel, pendency, peripheral, permission, Ponvory, prepackaged, Prinston, proprietary, Pvt, regularly, reissued, renewed, retrospectively, RYBREVANT, Shockwave, simplify, SKI, strongly, Supplementary, SWAV, synthetic, talquetamab, TALVEY, Tanabe, TDP, Torrent, Umedica, undergoing, war
Removed:
acceleration, AD, added, admission, advancing, agree, Alembic, amounting, anticipation, apply, approve, argument, assist, Atopic, auditing, authorizing, bermekimab, buyer, cardiogenic, conform, consisted, CPR, CVR, delivered, deny, directing, disposition, Edley, endpoint, entitling, establishment, exhausting, FASPRO, finalize, finalized, finalizing, fraudulently, gain, Genmab, growing, handful, heart, high, holder, HS, independent, industrial, ineligible, infarction, initially, innovator, investigate, investigational, IOL, IPO, IRS, Israeli, jury, largest, lift, mentioned, met, milled, mined, myocardial, nationwide, negotiating, Noramco, offering, oral, original, owed, paliperidone, partial, participation, PCI, pipeline, pre, premarket, premium, prepare, Prevention, Pty, purpose, ranged, recommendation, recommending, reconsideration, recovery, rehearing, reject, relation, release, removed, repayment, retained, revolving, rolling, secure, shock, softer, STEMI, submitted, sun, Suppurativa, Tasmanian, tender, threshold, tribal, unanimously, unapproved, unmet, upfront, wholly, Windsor, wrongdoing, XBiotech, XEPLION
Filing tables
Filing exhibits
Related press release
Associated JNJ transcripts
JNJ similar filings
Filing view
External links
Exhibit 32.2
CERTIFICATION OF CHIEF FINANCIAL OFFICER
PURSUANT TO SECTION 906 OF THE SARBANES-OXLEY ACT
The undersigned, Joseph J. Wolk, the Chief Financial Officer of Johnson & Johnson, a New Jersey corporation (the “Company”), pursuant to 18 U.S.C. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, hereby certifies that, to the best of my knowledge:
(1) the Company's Quarterly Report on Form 10-Q for the quarterly period ended March 31, 2024 (the “Report”) fully complies with the requirements of Section 13(a) of the Securities Exchange Act of 1934; and
(2) the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.
/s/ Joseph J. Wolk | ||
Joseph J. Wolk Chief Financial Officer | ||
Dated: May 1, 2024
This certification is being furnished to the SEC with this Report pursuant to Section 906 of the Sarbanes-Oxley Act of 2002 and shall not, except to the extent required by such Act, be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to liability of that section.